TMAO promotes NLRP3 inflammasome activation by inhibiting the sirtuin 3 (SIRT3)–superoxide dismutase 2 (SOD2)–mitochondrial ROS signaling pathway, leading to cardiovascular inflammation and worsening the pathological progression of AF and AS. This evidence concerns the gene NLRP3 and atrial fibrillation.